23 patents
Utility
Fused Heteroaromatic Pyrrolidinones
21 Sep 23
Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
Filed: 12 Jan 23
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
5 Jan 23
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 13 May 21
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
17 Nov 22
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing CHEN, Roland Joseph BILLEDEAU, Jim LI, Timothy Friend STANTON
Filed: 18 Jun 20
Utility
Fused Heteroaromatic Pyrrolidinones
29 Sep 22
Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
Filed: 21 Jun 19
Utility
Combination Therapy with Glutaminase Inhibitors and Immuno-oncology Agents
25 Nov 21
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
Filed: 4 Mar 21
Utility
Heterocyclic Glutaminase Inhibitors
23 Sep 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
Filed: 5 Oct 20
Utility
Compositions and Methods for Inhibiting Arginase Activity
26 Aug 21
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
Filed: 20 Jan 21
Utility
Conjoint Therapy with Glutaminase Inhibitors
17 Jun 21
The invention relates to methods of treating cancer using novel heterocyclic glutaminase inhibitor compounds conjointly with a PD1 or PD-L1 inhibitor.
Keith Orford
Filed: 1 Nov 18
Utility
Method of Preparing (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE
27 May 21
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Michael VAN ZANDT, Jennifer L. SAVOY
Filed: 1 Feb 21
Utility
Compositions and Methods for Inhibiting Arginase Activity
18 Mar 21
The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent.
Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
Filed: 19 Nov 20
Utility
Compositions and Methods for Inhibiting Arginase Activity
4 Mar 21
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention.
Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
Filed: 12 Nov 20
Utility
Compositions and Methods for Inhibiting Arginase Activity
28 Oct 20
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
Filed: 13 Feb 20
Utility
Compositions and Methods for Inhibiting Arginase Activity
15 Jul 20
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention.
Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
Filed: 22 Mar 20
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
15 Jul 20
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 18 Dec 19
Utility
Heterocyclic Inhibitors of Glutaminase
27 May 20
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric B. Sjogren
Filed: 5 Dec 19
Utility
Method of Preparing (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE
18 Mar 20
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Michael C. VAN ZANDT, Jennifer L. SAVOY
Filed: 17 Nov 19
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
18 Mar 20
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 26 Sep 19
Utility
Combination Therapy with Glutaminase Inhibitors
5 Feb 20
The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and a second anticancer agent such as osimertinib, pazopanib, navitoclax, palbociclib, or olaparib.
Susan D. Bromley, Francesco Parlati, Matthew I. Gross, Keith Orford
Filed: 8 Mar 18
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
25 Dec 19
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing Chen, Roland Joseph Billedeau, Jin Li
Filed: 19 Jun 19
Utility
Crystal Forms of Glutaminase Inhibitors
27 Nov 19
The invention relates to crystalline salts of a compound having the structure of formula (I), methods for their preparation, and related pharmaceutical compositions comprising the crystalline salt.
Timothy F. Stanton, James J. Springer, Jacqueline N. Williams
Filed: 6 Jun 19